# Case 004: Allergy Cross-Sensitivity

**Module Demonstrated:** Allergy Cross-Check Module (ACM-v1.0)  
**Scenario:** Evaluating cephalosporin use in patient with penicillin allergy

---

## Clinical Scenario

A 45-year-old woman with documented penicillin allergy (hives 20 years ago) presents with cellulitis requiring antibiotics. The physician is considering cephalexin.

### Query to Medical Engine

```
45yo female with penicillin allergy (hives, 20 years ago).
Cellulitis requiring oral antibiotics.
Is cephalexin safe?
```

---

## Medical Engine v2.6 Processing

### Smart Prompt Parser (SPP) Extraction

```json
{
  "patient": {
    "age": 45,
    "sex": "female"
  },
  "allergies": [{
    "drug": "penicillin",
    "reaction": "hives",
    "timing": "20 years ago",
    "reaction_type": "probable Type I (urticaria)"
  }],
  "condition": "cellulitis",
  "medication_query": "cephalexin",
  "query_type": "ALLERGY_SAFETY"
}
```

### ACM Module Activation

```
ALLERGY CROSS-CHECK INITIATED
â”œâ”€ Documented allergy: Penicillin
â”œâ”€ Reaction: Hives (urticaria)
â”œâ”€ Proposed: Cephalexin (1st-gen cephalosporin)
â”œâ”€ Cross-reactivity category: Beta-lactam
```

---

## Medical Engine Response

```
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ğŸ“‹ MEDICAL ENGINE v2.5 â€” ALLERGY CROSS-CHECK
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

PATIENT: 45-year-old female
DOCUMENTED ALLERGY: Penicillin (hives, 20 years ago)
PROPOSED MEDICATION: Cephalexin (1st-generation cephalosporin)

CONFIDENCE: HIGH
EVIDENCE LEVEL: I (Multiple meta-analyses)

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
âš ï¸ CROSS-SENSITIVITY ANALYSIS
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

HISTORICAL BELIEF (OUTDATED):
â”œâ”€ 10% cross-reactivity between penicillins and cephalosporins
â”œâ”€ This was based on early studies with contaminated products
â””â”€ NO LONGER CONSIDERED ACCURATE

CURRENT EVIDENCE (2020s):
â”œâ”€ True cross-reactivity: 1-2% for 1st-gen cephalosporins
â”œâ”€ Even lower for 2nd-4th gen: <0.5%
â”œâ”€ Cross-reactivity is related to SIDE CHAIN similarity
â””â”€ NOT the beta-lactam ring itself

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ğŸ“Š RISK STRATIFICATION FOR THIS PATIENT
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

REACTION SEVERITY: MODERATE
â”œâ”€ Hives (urticaria) suggests possible IgE-mediated
â”œâ”€ Not anaphylaxis = lower risk
â”œâ”€ Remote history (20 years) = allergies often wane

CROSS-REACTIVITY RISK:
â”œâ”€ Cephalexin (1st-gen): ~1-2% cross-reactivity
â”œâ”€ Similar R1 side chain to ampicillin
â”œâ”€ Overall risk: LOW but not zero

CLINICAL DECISION:
â”œâ”€ Risk level: LOW
â”œâ”€ Cephalexin likely SAFE with monitoring
â”œâ”€ OR consider non-beta-lactam alternative

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
âœ“ OPTIONS FOR THIS PATIENT
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

OPTION 1: USE CEPHALEXIN (Acceptable approach)
â”œâ”€ True cross-reactivity rate ~1-2%
â”œâ”€ Reaction was hives, not anaphylaxis
â”œâ”€ Precautions:
â”‚   â”œâ”€ First dose in monitored setting (30-60 min observation)
â”‚   â”œâ”€ Prescribe epinephrine auto-injector or ensure access
â”‚   â”œâ”€ Educate patient on warning signs
â”‚   â””â”€ Document informed consent

OPTION 2: ALTERNATIVE CEPHALOSPORIN
â”œâ”€ Consider cefdinir or cefpodoxime (3rd-gen)
â”œâ”€ Different side chain structure
â”œâ”€ Even lower cross-reactivity (<0.5%)

OPTION 3: NON-BETA-LACTAM ALTERNATIVES
â”œâ”€ Clindamycin 300-450mg TID Ã— 7-10 days
â”‚   â””â”€ Excellent skin coverage, no cross-reactivity
â”œâ”€ TMP-SMX DS BID Ã— 7-10 days
â”‚   â””â”€ Good for MRSA coverage if concern
â”œâ”€ Doxycycline 100mg BID Ã— 7-10 days
â”‚   â””â”€ Broad spectrum, no cross-reactivity

OPTION 4: ALLERGY TESTING
â”œâ”€ Penicillin skin testing available
â”œâ”€ If negative: Confirms safe to use penicillins/cephalosporins
â”œâ”€ Consider for patients with multiple infections
â”œâ”€ May take time to arrange (not for urgent cellulitis)

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
â„¹ï¸ MYTH CORRECTION
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

OUTDATED TEACHING:
"All patients with penicillin allergy should avoid cephalosporins"

CURRENT EVIDENCE:
â”œâ”€ Most PCN-allergic patients tolerate cephalosporins safely
â”œâ”€ Risk is ~1% for 1st-gen, <1% for later generations
â”œâ”€ True IgE-mediated PCN allergy is rare (<1% of labeled)
â”œâ”€ Many "penicillin allergies" are not true allergies

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ğŸ“‹ RECOMMENDED APPROACH
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

GIVEN THIS PATIENT:
â”œâ”€ Remote reaction (20 years ago)
â”œâ”€ Hives (not anaphylaxis)
â”œâ”€ Need for skin infection coverage

RECOMMENDATION:
â”œâ”€ Cephalexin is REASONABLE with monitoring
â”œâ”€ OR clindamycin if provider prefers to avoid any risk
â”œâ”€ Document risk-benefit discussion

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
âœ“ VERIFICATION REQUIRED
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

â–¡ Confirm details of original reaction
â–¡ Assess for any beta-lactam use since then
â–¡ Discuss options with patient
â–¡ Document informed decision
â–¡ Ensure emergency treatment available if cephalosporin used
â–¡ Provider sign-off

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ğŸ“ AUDIT TRAIL
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Timestamp: 2025-11-25T09:45:00Z
Modules: SPP, ACM activated
Cross-sensitivity: LOW risk
Alternatives provided: 4 options
Guideline: AAAAI/ACAAI practice parameter

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## Why This Case Matters

### Penicillin Allergy is Over-Labeled

- ~10% of patients report penicillin allergy
- True IgE-mediated allergy is <1%
- Many patients avoid beneficial beta-lactams unnecessarily

### Medical Engine Protections

1. **Evidence-based risk assessment** - Uses current data, not outdated 10% myth
2. **Reaction severity stratification** - Hives vs. anaphylaxis matters
3. **Multiple options** - Both beta-lactam and alternative pathways
4. **Myth correction** - Updates outdated beliefs

### Without Medical Engine

A provider might:
- Unnecessarily avoid all cephalosporins
- Prescribe broader-spectrum, less effective alternatives
- Not offer allergy testing option

### With Medical Engine

- Current evidence presented (1-2% true cross-reactivity)
- Risk stratified for specific patient
- Multiple safe pathways offered
- Myth about 10% cross-reactivity corrected

---

## Validation Metrics

| Metric | This Case | Target |
|--------|-----------|--------|
| Cross-sensitivity assessment | Evidence-based | >95% |
| Myth correction | Included | Required |
| Alternatives provided | 4 options | Required |
| Documentation guidance | Complete | Required |

---

**Case Version:** 1.0  
**Last Updated:** November 2025
